Diligence memo · auto-generated · as of July 2, 2026
Mimerigen, Inc.
Mimerigen, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Mimerigen, Inc. operates in Biotechnology, based in GUILFORD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Mimerigen, Inc. has raised $105K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $105K on 2024-07-17.
Most recent recorded round closed around 2024-07-17.
Valuation (modeled)modeled
Provath models Mimerigen, Inc. at approximately $472K (range $56K–$1.6M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.15× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 23 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 1% of Biotechnology peers (4293 compared).
Modeled value ranks above 1% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.